PMID- 20298180
OWN - NLM
STAT- MEDLINE
DCOM- 20100611
LR  - 20151119
IS  - 1470-8752 (Electronic)
IS  - 0300-5127 (Linking)
VI  - 38
IP  - 2
DP  - 2010 Apr
TI  - Biomarkers in Barrett's oesophagus.
PG  - 343-7
LID - 10.1042/BST0380343 [doi]
AB  - Biomarkers are needed to screen multiple stages in the clinical pathway of 
      Barrett's oesophagus patients; from disease diagnosis to risk stratification and 
      predicting response to therapy. Routes to the identification of biomarkers have 
      been recognized by known molecular features of the disease and more recently 
      through transcriptomic, methylation and proteomic screening approaches. The 
      majority of Barrett's oesophagus patients remain undiagnosed in the general 
      population. In order to develop a tool to screen for Barrett's oesophagus in the 
      primary care setting, minimally invasive sampling methods coupled with 
      immunocytology-based biomarkers are currently being assessed. Biomarkers may also 
      have utility in surveillance programmes by allowing endoscopic interval to be 
      adjusted according to individual neoplastic risk. Many individual biomarkers have 
      been proposed in this regard, but have frequently been assessed in studies of 
      limited power, or have lacked sufficient sensitivity or specificity when assessed 
      in wider population-based studies. Biomarker panels may provide a route forward. 
      In this regard, a panel of methylation markers has shown promise in a 
      multicentre, double-blind, validation study. Biomarkers are also being developed 
      to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, 
      utilizing brush cytology combined with FISH (fluorescence in situ hybridization), 
      and to assess therapeutic success and risk of complication during photodynamic 
      therapy. Finally, we outline progress in identifying alternative sources of 
      biomarkers for this condition.
FAU - Huang, Qizhi
AU  - Huang Q
AD  - Molecular Epidemiology Unit, Leeds Institute of Genetics, Health and 
      Therapeutics, LIGHT Laboratories, University of Leeds, Leeds LS2 9JT, UK.
FAU - Hardie, Laura J
AU  - Hardie LJ
LA  - eng
GR  - C11347/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Biochem Soc Trans
JT  - Biochemical Society transactions
JID - 7506897
RN  - 0 (Biomarkers)
RN  - 0 (Biomarkers, Pharmacological)
SB  - IM
MH  - Animals
MH  - Barrett Esophagus/*diagnosis/epidemiology/*genetics/therapy
MH  - Biomarkers/*analysis/metabolism
MH  - Biomarkers, Pharmacological/analysis
MH  - Disease Progression
MH  - Humans
MH  - Mass Screening/methods
MH  - Population
MH  - Prognosis
RF  - 50
EDAT- 2010/03/20 06:00
MHDA- 2010/06/12 06:00
CRDT- 2010/03/20 06:00
PHST- 2010/03/20 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/06/12 06:00 [medline]
AID - BST0380343 [pii]
AID - 10.1042/BST0380343 [doi]
PST - ppublish
SO  - Biochem Soc Trans. 2010 Apr;38(2):343-7. doi: 10.1042/BST0380343.